Slide 1: Orion Half-Year Financial Report January-June 2025
Orion Half-Year Financial Report January-June 2025 18 July 2025
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Q2 2025 Highlights
Q2 2025 Highlights • FDA approval and CHMP recommendation for darolutamide + ADT in patients with mHSPC • MSD expanding opevesostat program to women’s cancers • Capital Markets Day in May • Orion’s first biologics expected to enter clinical phase in the next 12-24 months • Easyhaler® peak sales pote
Slide 4: Q2 2025 Financial highlights
Q2 2025 Financial highlights Net sales, EUR million Operating profit, EUR million Operating cash flow per share, EUR Operating profit margin 25.1% (20.1%) +26.9% +58.9% +189.7% 416.5 104.6 0.57 328.2 65.8 0.20 Q2/2024 Q2/2025 Q2/2024 Q2/2025 Q2/2024 Q2/2025 4 18 July 2025 © Orion Corporation
Slide 5: Net sales bridge (MEUR) from Q2/24 to Q2/25
Net sales bridge (MEUR) from Q2/24 to Q2/25 6.9 -2.1 -0.9 416.5 9.4 8.5 328.2 66.5 Q2/2024 1 2 3 4 5 6 Q2/2025 1 Innovative Medicines 4 Animal Health 2 Branded Products 5 Fermion 3 Generics and Consumer Health 6 Translation differences and other operations 5 18 July 2025 © Orion Corporation The figu
Slide 6: Operating profit bridge (MEUR) Q2/24 to Q2/25
Operating profit bridge (MEUR) Q2/24 to Q2/25 -0.1 1.6 -22.0 104.6 45.6 -14.5 30.1 -2.0 65.8 Q2/2024 1 2 3 4 5 6 7 Q2/2025 1 Change in sales volume 5 Milestones 2 Changes in prices, COGS and product mix 6 Other operating income and expenses 3 Exchange rate effect on gross margin 7 Fixed cost 4 Royal
Slide 7: H1 2025 Financial highlights
H1 2025 Financial highlights Net sales, EUR million Operating profit, EUR million Operating cash flow per share, EUR Operating profit margin 23.7% (19.1%) +21.1% +49.8% +14.1% 771.0 182.5 1.12 0.98 636.7 121.8 H1/2024 H1/2025 H1/2024 H1/2025 H1/2024 H1/2025 7 18 July 2025 © Orion Corporation
Slide 8: Innovative Medicines
Innovative Medicines +83.1% +77.8% Nubeqa® sales (MEUR) 146.7 244.5 152 6.6 12.9 140 36 44 95 92 80.1 137.5 8.5 16.4 72 26 140.1 231.6 62 38 50 21 116 22 96 37 18 71.6 121.1 69 11 MEUR MEUR 51 54 41 32 27 Q2/2024 Q2/2025 H1/2024 H1/2025 2023 2023 2024 2024 2024 2024 2025 2025 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Slide 9: Branded Products
Branded Products +13.2% +11.4% • Respiratory product portfolio 80.4 157.4 growth driven by Easyhaler® 71.0 7.9 141.2 15.0 budesonide-formoterol 6.3 11.8 combination product 28.2 51.5 • CNS sales growing mainly due to 24.3 46.4 entacapone sales in Japan • License agreement with Criceto on APORON®, a
Slide 10: Generics and Consumer Health
Generics and Consumer Health 6.7% 3.7% • New launches and good 135.0 266.7 availability of Orion products in 126.5 257.2 Finland supported growth 31.1 64.4 30.5 64.4 • Good availability of Orion products in Scandinavia supported growth 96.0 103.8 192.8 202.2 MEUR MEUR Q2/2024 Q2/2025 H1/2024 H1/2025
Slide 11: Animal Health
Animal Health +22.9% +16.4% • The growth came from various 36.8 72.0 different products and regions 61.8 30.0 10.4 19.2 8.6 18.8 26.4 52.8 21.4 43.0 MEUR MEUR Q2/2024 Q2/2025 H1/2024 H1/2025 Other products Sedatives product portfolio 11 18 July 2025 © Orion Corporation
Slide 12: TOP products and net sales split in H1/2025
TOP 10 products and net sales split in H1/2025 EUR vs. Product or product portfolio million H1/2024 1. Nubeqa® 231.6 +91.2% 4% 9% 2. Easyhaler® product portfolio 88.9 +9.5% 3. Entacapone products1 46.3 +7.1% 32% 4. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 19.2 +2.1% 5. Divina® series 15.0 +26.9
Slide 13: Orion's key clinical development pipeline
Orion’s key clinical development pipeline Developed by Trial/compound Indication (or modality for pre-clinical assets) Phase I Phase II Phase III Registration ARANOTE (darolutamide) metastatic hormone-sensitive prostate cancer ARASTEP (darolutamide) BCR (prostate cancer) DASL-HiCaP (darolutamide) (N
Slide 14: Orion's climate targets are backed by science
Orion’s climate targets are backed by science Validation from the Science Based Targets initiative (SBTi) confirms that our near-term emissions reduction targets are in line with the latest climate science 70% 78% Orion commits to reduce absolute scope Orion commits that 78% of its suppliers by emis
Slide 15: Scope 1&2: emissions reduction roadmap for Orion's own operations
Scope 1&2: emissions reduction roadmap for Orion’s own operations Planned actions towards the first of our near-term targets Combined scope 1 & 2 GHG emissions by decarbonization lever tCO2e Reported data Reduction percentages are relative to 2023 base year less previous years’ reductions. • Process
Slide 16: Outlook for 2025
Outlook for 2025 (provided on 9 July 2025) Net sales EUR 1,630–1,730 million Operating profit EUR 400–500 million 16 18 July 2025 © Orion Corporation
Slide 17: Upcoming events
Upcoming events Interim Report 1–9/2025 28/10/2025 Financial Statement Release for 2025 12/2/2026 AGM planned to be held 24/3/2026 Interim Report 1–3/2026 23/4/2026 Half-Year Financial Report 1–6/2026 17/7/2026 Interim Report 1–9/2026 28/10/2026 The Financial Statements and the Report by the Board o